Literature DB >> 22492942

Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats.

Jorge F Giani1, Valeria Burghi, Luciana C Veiras, Analía Tomat, Marina C Muñoz, Gabriel Cao, Daniel Turyn, Jorge E Toblli, Fernando P Dominici.   

Abstract

Angiotensin (ANG)-(1-7) is known to attenuate diabetic nephropathy; however, its role in the modulation of renal inflammation and oxidative stress in type 2 diabetes is poorly understood. Thus in the present study we evaluated the renal effects of a chronic ANG-(1-7) treatment in Zucker diabetic fatty rats (ZDF), an animal model of type 2 diabetes and nephropathy. Sixteen-week-old male ZDF and their respective controls [lean Zucker rats (LZR)] were used for this study. The protocol involved three groups: 1) LZR + saline, 2) ZDF + saline, and 3) ZDF + ANG-(1-7). For 2 wk, animals were implanted with subcutaneous osmotic pumps that delivered either saline or ANG-(1-7) (100 ng·kg(-1)·min(-1)) (n = 4). Renal fibrosis and tissue parameters of oxidative stress were determined. Also, renal levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), ED-1, hypoxia-inducible factor-1α (HIF-1α), and neutrophil gelatinase-associated lipocalin (NGAL) were determined by immunohistochemistry and immunoblotting. ANG-(1-7) induced a reduction in triglyceridemia, proteinuria, and systolic blood pressure (SBP) together with a restoration of creatinine clearance in ZDF. Additionally, ANG-(1-7) reduced renal fibrosis, decreased thiobarbituric acid-reactive substances, and restored the activity of both renal superoxide dismutase and catalase in ZDF. This attenuation of renal oxidative stress proceeded with decreased renal immunostaining of IL-6, TNF-α, ED-1, HIF-1α, and NGAL to values similar to those displayed by LZR. Angiotensin-converting enzyme type 2 (ACE2) and ANG II levels remained unchanged after treatment with ANG-(1-7). Chronic ANG-(1-7) treatment exerts a renoprotective effect in ZDF associated with a reduction of SBP, oxidative stress, and inflammatory markers. Thus ANG-(1-7) emerges as a novel target for treatment of diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22492942     DOI: 10.1152/ajprenal.00063.2012

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  28 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

2.  Lack of weight gain after angiotensin AT1 receptor blockade in diet-induced obesity is partly mediated by an angiotensin-(1-7)/Mas-dependent pathway.

Authors:  Johanna Schuchard; Martina Winkler; Ines Stölting; Franziska Schuster; Florian M Vogt; Jörg Barkhausen; Christoph Thorns; Robson A Santos; Michael Bader; Walter Raasch
Journal:  Br J Pharmacol       Date:  2015-06-12       Impact factor: 8.739

3.  Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy.

Authors:  Jan Wysocki; Minghao Ye; Ahmed M Khattab; Agnes Fogo; Aline Martin; Nicolae Valentin David; Yashpal Kanwar; Mark Osborn; Daniel Batlle
Journal:  Kidney Int       Date:  2016-12-04       Impact factor: 10.612

4.  Angiotensin-(1-7) administration benefits cardiac, renal and progenitor cell function in db/db mice.

Authors:  A M Papinska; N M Mordwinkin; C J Meeks; S S Jadhav; K E Rodgers
Journal:  Br J Pharmacol       Date:  2015-07-30       Impact factor: 8.739

Review 5.  The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).

Authors:  Robson Augusto Souza Santos; Walkyria Oliveira Sampaio; Andreia C Alzamora; Daisy Motta-Santos; Natalia Alenina; Michael Bader; Maria Jose Campagnole-Santos
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

Review 6.  ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis.

Authors:  A C Simões e Silva; K D Silveira; A J Ferreira; M M Teixeira
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

Review 7.  Brain renin-angiotensin system in the nexus of hypertension and aging.

Authors:  Amy C Arnold; Patricia E Gallagher; Debra I Diz
Journal:  Hypertens Res       Date:  2012-10-18       Impact factor: 3.872

8.  Angiotensin-(1-7) Selectively Induces Relaxation and Modulates Endothelium-Dependent Dilation in Mesenteric Arteries of Salt-Fed Rats.

Authors:  Gábor Raffai; Julian H Lombard
Journal:  J Vasc Res       Date:  2016-09-28       Impact factor: 1.934

9.  Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!

Authors:  Vajir Malek; Sachin V Suryavanshi; Nisha Sharma; Yogesh A Kulkarni; Shrikant R Mulay; Anil Bhanudas Gaikwad
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

10.  Oral administration of angiotensin-(1-7) ameliorates type 2 diabetes in rats.

Authors:  Sérgio H S Santos; Jorge F Giani; Valeria Burghi; Johanna G Miquet; Fatimunnisa Qadri; Janaina F Braga; Mihail Todiras; Katarina Kotnik; Natalia Alenina; Fernando P Dominici; Robson A S Santos; Michael Bader
Journal:  J Mol Med (Berl)       Date:  2013-10-27       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.